Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cabtreo · 1 trial · 1 indication
Medication adherence measured by recording the weight of medication (in milligrams) in the bottle with electronic monitor attached
| Arm | Type | Description |
|---|---|---|
| One single fixed-combination product | EXPERIMENTAL | Participants instructed to apply clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel once daily |
| Two products | EXPERIMENTAL | Participants instructed to apply 0.3%/BPO 2.5% gel and compounded clindamycin phosphate 1.2% gel once daily |
| Three products | EXPERIMENTAL | Participants instructed to apply BPO 2.5% gel, adapalene 0.1% gel, and compounded clindamycin phosphate 1.2% gel once daily |
| Name | Type | Description |
|---|---|---|
| clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel | DRUG | Single topical treatment to be applied daily to area affected once daily. |
| adapalene 0.3%/BPO 2.5% gel and compounded clindamycin phosphate 1.2% gel | DRUG | Two topical treatments to be applied to area affected once daily. |
| Compounded BPO 2.5% gel, adapalene 0.1% gel, and compounded clindamycin phosphate 1.2% gel | DRUG | Three topical treatments to be applied to area affected once daily. |
Inclusion Criteria: 1. Adult patients ≥18 years of age 2. Patients with a current diagnosis of acne 3. Patients who live in the US, 4. Patients have sufficient command of the English language Exclusion Criteria: 1. Patients less than the age of 18 2. Patients without a current diagnosis of acne 3...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | 1% Clascoterone |
| Sanofi SA Sponsored ADR | SNY | 3 | PHASE1 | Acne mRNA vaccine |
| Hoth Therapeutics, Inc. | HOTH | 1 | PHASE2 | HT-001 2%, HT-001 1%, HT-001 0.5% |
| Sagimet Biosciences Inc. Class A | SGMT | 1 | PHASE1 | TVB-3567 |